need to meet timing limitations imposed by the review and funding cycle.

The meeting will be closed in accordance with provisions set forth in secs 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. The applications and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program Numbers: 93.277, Drug Abuse Scientist Development, Research Scientist Development, and Research Scientist Awards; 93.278, Drug Abuse National Research Service Awards for Research Training; 93.279, Drug Abuse Research Programs, National Institute of Health)

Dated: September 25, 1996.

Paula N. Hayes,

Acting Committee Management Officer, NIH. [FR Doc. 96–25015 Filed 9–27–96; 8:45 am] BILLING CODE 4140–01–M

#### National Institute on Drug Abuse; Notice of Closed Meetings

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings of the National Institute on Drug Abuse Initial Review Group.

*Purpose/Agenda:* To review and evaluate grant applications.

Name of Committee: Basic Behavioral Science Research Subcommittee.

Date: October 8-10, 1996.

Time: 8:30 a.m.

*Place:* Bethesda Marriott, 5151 Pooks Hill Road, Bethesda, MD 20814.

Contact Person: William C. Grace, Ph.D., Scientific Review Administrator, Office of Extramural Program Review, National Institute on Drug Abuse, 5600 Fishers Lane, Room 10–22, Telephone (301) 443–9042.

Name of Committee: Epidemiology and Prevention Research Subcommittee.

Date: October 8-10, 1996.

Time: 8:30 a.m.

*Place:* Double Tree Hotel, 1750 Rockville Pike, Rockville, MD 20852.

Contact Person: Raquel Crider, Ph.D., Scientific Review Administrator, Office of Extramural Program Review, National Institute on Drug Abuse, 5600 Fishers Lane, Room 10–22, Telephone (301) 443–9042.

This notice is being published less than 15 days prior to the meetings due to the urgent need to meet timing limitations imposed by the review and funding cycle.

Name of Committee: Human Development Research Subcommittee.

Date: October 15-16, 1996.

Time: 8:30 a.m.

*Place:* Bethesda Marriott, 5151 Pooks Hill Road, Bethesda, MD 20814.

Contact Person: Kesinee Nimit, M.D., Scientific Review Administrator, Office of Extramural Program Review, National Institute on Drug Abuse, 5600 Fishers Lane, Room 10–22, Telephone (301) 443–9042.

Name of Committee: Molecular, Cellular and Chemical Neurobiology Research Subcommittee.

Date: October 15-17, 1996.

Time: 8:30 a.m.

*Place:* Bethesda Marriott, 5151 Pooks Hill Road, Bethesda, MD 20814.

Contact Person: Rita Liu, Ph.D., Scientific Review Administrator, Office of Extramural Program Review, National Institute on Drug Abuse, 5600 Fishers Lane, Room 10–22, Telephone (301) 443–2620.

Name of Committee: Neuropharmacology Research Subcommittee.

Date: October 15-17, 1996.

Time: 8:30 a.m.

*Place:* Bethesda Marriott, 5151 Pooks Hill Road, Bethesda, MD 20814.

Contact Person: Syed Husain, Ph.D., Scientific Review Administrator, Office of Extramural Program Review, National Institute on Drug Abuse, 5600 Fishers Lane, Room 10–22, Telephone (301) 443–2620.

*Name of Committee:* Neurophysiology and Neuroanatomy Research Subcommittee.

Date: October 15-17, 1996.

Time: 8:30 a.m.

*Place*: Bethesda Marriott, 5151 Pooks Hill Road, Bethesda, MD 20814.

Contact Person: Gamil Debbas, Ph.D., Scientific Review Administrator, Office of Extramural Program Review, National Institute on Drug Abuse, 5600 Fishers Lane, Room 10–22, Telephone (301) 443–2620.

The meetings will be closed in accordance with provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. The applications and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications, disclosure of which would constitute a clearly unwarranted invasion of personal privacy. (Catalog of Federal Domestic Assistance Program Numbers: 93.277, Drug Abuse Research Scientist Development and Research Scientist Awards; 93.278, Drug Abuse National Research Service Awards for Research Training; 93.279, Drug Abuse

Dated: September 25, 1996.

Paula N. Hayes,

Research Programs)

Acting Committee Management Officer, NIH. [FR Doc. 96–25016 Filed 9–27–96; 8:45 am] BILLING CODE 4140–01–M

# National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Meeting of the Board of Scientific Counselors

Pursuant to Pub. L. 92–463, notice is hereby given of a meeting of the Board of Scientific Counselors, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), November 13–15, 1996, National Institutes of Health, Building 5, Room 127, Bethesda, Maryland 20892.

In accordance with the provisions set forth in secs. 552b(c)(6), Title 5, U.S.C. and sec. 10(d) of Pub. L. 92-463, the meeting will be closed to the public on November 13 from 7:00 p.m. to 10:00 p.m.; November 14 from 8:00 a.m. to 6:00 p.m. and on November 15 from 8:00 a.m. to ajournment for the review, discussion and evaluation of individual intramural programs and projects conducted by the NIDDK, including consideration of personnel qualifications and performance, the competence of individual investigators, and similar items, disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

A summary of the meeting and roster of members will be provided, upon request, by the Committee Management Office, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Natcher Building, Room 6AS-37J, Bethesda, Maryland 20892, (301) 594-8892. For any further information and for individuals who plan to attend and need special assistance such as sign language interpretation or other reasonable accommodations, please contact Dr. Allen Spiegel, Scientific Review Administrator, Board of Scientific Counselors. National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Building 10, Room 9N-222, Bethesda, Maryland 20892, (301) 496-4128, at least two weeks prior to the meeting

(Catalog of Federal Domestic Assistance Program No. 93.847–849, Diabetes, Endocrine and Metabolic Diseases; Digestive Diseases and Nutrition; and Kidney Diseases, Urology and Hematology Research, National Institutes of Health)

Dated: September 24, 1996.

Paula N. Hayes,

Acting Committee Management Officer, NIH. [FR Doc. 96–25017 Filed 9–27–96; 8:45 am] BILLING CODE 4140–01–M

# National Institute on Deafness and Other Communication Disorders; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting:

Name of Committee: Communication Disorders Review Committee.

Date: October 23-25, 1996.

Time: 8 a.m.–5:30 p.m., October 23, 8 a.m.–5:30 p.m., October 24, 8 a.m.–adjournment, October 25.

*Place:* Doubletree Hotel, 1750 Rockville Pike, Rockville, MD 20852.

Contact Person: Mary V. Nekola, Ph.D., Scientific Review Administrator, NIDCD/ DEA/SRB, EPS Room 400C, 6120 Executive Boulevard, MSC 7180, Bethesda, MD 20892– 7180, 301–496–8683.

*Purpose/Agenda:* To review and evaluate grant applications.

The meeting will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. The applications and/or proposals and the discussion could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program No. 93.173 Biological Research Related to Deafness and Communication Disorders)

Dated: September 24, 1996.

Paula N. Hayes,

Acting Committee Management Officer, NIH. [FR Doc. 96–25018 Filed 9–27–96; 8:45 am] BILLING CODE 4140–01–M

### National Institute of Dental Research; Notice of Closed Meetings

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following National Institute of Dental Research Special Emphasis Panel (SEP) meetings:

*Name of SEP:* National Institute of Dental Research Special Emphasis Panel-Review of Conf. Grant (97–09).

Dates: October 15, 1996.

Time: 1:00 p.m.

Place: National Institute of Health, 4500 Center Drive, Natcher Building, Room 4AN– 44F, Bethesda, MD 20892 (Teleconference).

Contact person: Dr. Yong Shin, Scientific Review Administrator, 4500 Center Drive, Natcher Building, Room 4AN–44F, Bethesda, MD 20892, (301) 594–2372.

Purpose/Agenda: To evaluate and review grant applications and/or contract proposals.

Name of SEP: National Institute of Dental Research Special Emphasis Panel-Review of Conf. Grants (97–04).

Dates: October 16, 1996.

Time: 1:30 p.m.

*Place:* National Institutes of Health, 4500 Center Drive, Natcher Building, Room 4AN-44F, Bethesda, MD 20892 (Teleconference).

Contact person: Dr. Yong Shin, Scientific Review Administrator, 4500 Center Drive, Natcher Building, Room 4AN–44F, Bethesda, MD 20892, (301) 594–2372.

Purpose/Agenda: To evaluate and review grant applications and/or contract proposals.

*Name of SEP:* National Institute of Dental Research Special Emphasis Panel-Review of Conf. Grant (97–10).

Dates: October 16, 1996.

Time: 12:00 noon.

*Place:* National Institutes of Health, 4500 Center Drive, Natcher Building, Room 4AN–44F, Bethesda, MD 20892 (Teleconference).

Contact person: Dr. Yong Shin, Scientific Review Administrator, 4500 Center Drive, Natcher Building, Room 4AN–44F, Bethesda, MD 20892, (301) 594–2372.

Purpose/Agenda: To evaluate and review grant applications and/or contract proposals.

Name of SEP: National Institute of Dental Research Special Emphasis Panel-Review of Conf. Grant (97–02).

Dates: October 18, 1996.

Time: 8:00 a.m.

*Place*: National Institutes of Health, 4500 Center Drive, Natcher Building, Room 4AN– 44F, Bethesda, MD 20892 (Teleconference).

Contact person: Dr. Yong Shin, Scientific Review Administrator, 4500 Center Drive, Natcher Building, Room 4AN–44F, Bethesda, MD 20892, (301) 594–2372.

Purpose/Agenda: To evaluate and review grant applications and/or contract proposals.

This notice is being published less than fifteen days prior to the meetings due to the urgent need to meet timing limitations imposed by the review and funding cycle.

The meetings will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. (Catalog of Federal Domestic Assistance Program No. 93.121, Oral Diseases and Disorders Research)

Dated: September 24, 1996.

Paula N. Hayes,

Acting Committee Management Specialist, NIH.

[FR Doc. 96–25019 Filed 9–27–96; 8:45 am] BILLING CODE 4140–01–M

# National Institute of Neurological Disorders and Stroke; Division of Extramural Activities; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting:

Name of Committee: National Institute of Neurological Disorders and Stroke Special Emphasis Panel.

Date: October 15–16, 1996.

Time: Beginning October 15, 7 p.m. Place: Holiday Inn Bethesda, 8120 Wisconsin Avenue, Bethesda, MD 20814.

Contact Person: Dr. Howard Weinstein, Scientific Review Administrator, National Institutes of Health, 7550 Wisconsin Avenue, Room 9C10, Bethesda, MD 20892, (301) 496– 9223

*Purpose/Agenda:* To review and evaluate a grant application.

The meeting will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

This notice is being published less than fifteen days prior to the meeting due to the urgent need to meet timing limitations imposed by the review and funding cycle. (Catalog of Federal Domestic Assistance Program No. 93.853, Clinical Research Related to Neurological Disorders; No. 93.854, Biological Basis Research in the Neurosciences)

Dated: September 24, 1996.

Paula N. Hayes,

Acting Committee Management Officer, NIH. [FR Doc. 96–25020 Filed 9–27–96; 8:45 am] BILLING CODE 4140–01–M

# Prospective Grant of Exclusive License: Synthesis of Medical Opiate Compounds

**AGENCY:** National Institutes of Health, Public Health Service, DHHS. **ACTION:** Notice.

**SUMMARY:** This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of an exclusive license in the United States to practice the invention embodied in: U.S. Patent No. 4,410,700, issued October 18, 1983 (U.S. Patent Application Serial No. 06/ 265,469, filed May 20, 1981), entitled "Preparation of Chiral 1-Benzyl-1,2,3,4-Tetrahydroisoquinolines by Optical Resolution"; U.S. Patent No. 4,521,601, issued June 4, 1985 (U.S. Patent Application Serial No. 06/477,970, filed March 23, 1983), entitled "Practical **Total Synthesis Unnatural Enantiomers** of Opium Derived Morphinans"; U.S. Patent No. 4,556,712, issued December 3, 1985 (U.S. Patent Application Serial No. 06/476,830, filed March 18, 1983), entitled "Preparation and Racemization of Chiral 1-Benzyl-1,2,3,4-Tetrahydroisoquinolines"; U.S. Patent No. 4,613,668, issued September 23, 1986 (U.S. Patent Application Serial No. 06/564,515, filed December 22, 1983), entitled "Short Total Synthesis of Morphinan Compounds Which Uses Cyclization of a Cycloalkylcarbonyl Compound Selected from Cyclopropylcarbonyl Cyclobutylcarbonyl"; U.S. Patent No. 4,727,146, issued February 23, 1988 (U.S. Patent Application Serial No. 06/